Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 1 to 12 of 259 entries
Sorted by: Best Match Show Resources per page
Reversing factor Xa inhibitors - clinical utility of andexanet alfa.

Journal of blood medicine

Kaatz S, Bhansali H, Gibbs J, Lavender R, Mahan CE, Paje DG.
PMID: 28979172
J Blood Med. 2017 Sep 13;8:141-149. doi: 10.2147/JBM.S121550. eCollection 2017.

Approximately half of patients started on an oral anticoagulant in the USA now receive one of the newer direct oral anticoagulants (DOACs). Although there is an approved reversal agent for the direct thrombin inhibitor dabigatran, a specific reversal agent...

Cite
Kaatz S, Bhansali H, Gibbs J, et al. Reversing factor Xa inhibitors - clinical utility of andexanet alfa. J Blood Med. 2017;8:141-149doi: 10.2147/JBM.S121550.
Kaatz, S., Bhansali, H., Gibbs, J., Lavender, R., Mahan, C. E., & Paje, D. G. (2017). Reversing factor Xa inhibitors - clinical utility of andexanet alfa. Journal of blood medicine, 8141-149. https://doi.org/10.2147/JBM.S121550
Kaatz, Scott, et al. "Reversing factor Xa inhibitors - clinical utility of andexanet alfa." Journal of blood medicine vol. 8 (2017): 141-149. doi: https://doi.org/10.2147/JBM.S121550
Kaatz S, Bhansali H, Gibbs J, Lavender R, Mahan CE, Paje DG. Reversing factor Xa inhibitors - clinical utility of andexanet alfa. J Blood Med. 2017 Sep 13;8:141-149. doi: 10.2147/JBM.S121550. eCollection 2017. PMID: 28979172; PMCID: PMC5602457.
Copy Download .nbib Format: NLM
[Comparison of Novel Oral Anticoagulants and Warfarin in Elderly Patients With Nonvalvular Atrial Fibrillation].

Kardiologiia

Shevelev VI, Kanorsky SG.
PMID: 28294796
Kardiologiia. 2015 Oct;55(10):58-63. doi: 10.18565/cardio.2015.10.58-63.

We compared efficacy and safety of warfarin with those of direct thrombin inhibitor dabigatran, factor Xa inhibitors rivaroxaban and apixaban used for stroke prevention in 280 patients aged 65-80 years with non-valvular atrial fibrillation. Treatment for two years with...

Cite
Shevelev VI, Kanorsky SG. [Comparison of Novel Oral Anticoagulants and Warfarin in Elderly Patients With Nonvalvular Atrial Fibrillation]. Kardiologiia. 2015;55(10):58-63doi: 10.18565/cardio.2015.10.58-63.
Shevelev, V. I., & Kanorsky, S. G. (2015). [Comparison of Novel Oral Anticoagulants and Warfarin in Elderly Patients With Nonvalvular Atrial Fibrillation]. Kardiologiia, 55(10), 58-63. https://doi.org/10.18565/cardio.2015.10.58-63
Shevelev, V I, and Kanorsky, S G. "[Comparison of Novel Oral Anticoagulants and Warfarin in Elderly Patients With Nonvalvular Atrial Fibrillation]." Kardiologiia vol. 55,10 (2015): 58-63. doi: https://doi.org/10.18565/cardio.2015.10.58-63
Shevelev VI, Kanorsky SG. [Comparison of Novel Oral Anticoagulants and Warfarin in Elderly Patients With Nonvalvular Atrial Fibrillation]. Kardiologiia. 2015 Oct;55(10):58-63. doi: 10.18565/cardio.2015.10.58-63. Russian. PMID: 28294796.
Copy Download .nbib Format: NLM
Stroke Prevention with Oral Anticoagulants: Summary of the Evidence and Efficacy Measures as an Aid to Treatment Choices.

Cardiology and therapy

Saraiva JFK.
PMID: 29488150
Cardiol Ther. 2018 Jun;7(1):15-24. doi: 10.1007/s40119-018-0106-1. Epub 2018 Feb 27.

Atrial fibrillation (AF) is an established risk factor for a first or recurrent stroke. Despite proven efficacy in preventing stroke in patients with AF, warfarin is underused, partly due to safety concerns. Recent randomized trials have shown that non-vitamin...

Cite
Saraiva JFK. Stroke Prevention with Oral Anticoagulants: Summary of the Evidence and Efficacy Measures as an Aid to Treatment Choices. Cardiol Ther. 2018;7(1):15-24doi: 10.1007/s40119-018-0106-1.
Saraiva, J. F. K. (2018). Stroke Prevention with Oral Anticoagulants: Summary of the Evidence and Efficacy Measures as an Aid to Treatment Choices. Cardiology and therapy, 7(1), 15-24. https://doi.org/10.1007/s40119-018-0106-1
Saraiva, José Francisco Kerr. "Stroke Prevention with Oral Anticoagulants: Summary of the Evidence and Efficacy Measures as an Aid to Treatment Choices." Cardiology and therapy vol. 7,1 (2018): 15-24. doi: https://doi.org/10.1007/s40119-018-0106-1
Saraiva JFK. Stroke Prevention with Oral Anticoagulants: Summary of the Evidence and Efficacy Measures as an Aid to Treatment Choices. Cardiol Ther. 2018 Jun;7(1):15-24. doi: 10.1007/s40119-018-0106-1. Epub 2018 Feb 27. PMID: 29488150; PMCID: PMC5986671.
Copy Download .nbib Format: NLM
Reversal Strategies for Intracranial Hemorrhages in Patients Taking Oral Factor Xa Inhibitors.

Hospital pharmacy

Karli B, Bartel B, Pavelko R.
PMID: 26448667
Hosp Pharm. 2015 Jul;50(7):569-77. doi: 10.1310/hpj5007-569. Epub 2015 Jul 31.

Factor Xa (fXa) inhibitors are becoming more common in clinical practice due to a variety of reasons. Unfortunately, limited data are currently available on the safe and efficacious reversal of these agents. This series presents 3 patient cases of...

Cite
Karli B, Bartel B, Pavelko R. Reversal Strategies for Intracranial Hemorrhages in Patients Taking Oral Factor Xa Inhibitors. Hosp Pharm. 2015;50(7):569-77doi: 10.1310/hpj5007-569.
Karli, B., Bartel, B., & Pavelko, R. (2015). Reversal Strategies for Intracranial Hemorrhages in Patients Taking Oral Factor Xa Inhibitors. Hospital pharmacy, 50(7), 569-77. https://doi.org/10.1310/hpj5007-569
Karli, Betsy, et al. "Reversal Strategies for Intracranial Hemorrhages in Patients Taking Oral Factor Xa Inhibitors." Hospital pharmacy vol. 50,7 (2015): 569-77. doi: https://doi.org/10.1310/hpj5007-569
Karli B, Bartel B, Pavelko R. Reversal Strategies for Intracranial Hemorrhages in Patients Taking Oral Factor Xa Inhibitors. Hosp Pharm. 2015 Jul;50(7):569-77. doi: 10.1310/hpj5007-569. Epub 2015 Jul 31. PMID: 26448667; PMCID: PMC4589860.
Copy Download .nbib Format: NLM
Newer Oral Anticoagulants: Stroke Prevention and Pitfalls.

The open cardiovascular medicine journal

Patel A, Goddeau RP, Henninger N.
PMID: 27347226
Open Cardiovasc Med J. 2016 May 27;10:94-104. doi: 10.2174/1874192401610010094. eCollection 2016.

Warfarin is very effective in preventing stroke in patients with atrial fibrillation. However, its use is limited due to fear of hemorrhagic complications, unpredictable anticoagulant effects related to multiple drug interactions and dietary restrictions, a narrow therapeutic window, frequent...

Cite
Patel A, Goddeau RP, Henninger N. Newer Oral Anticoagulants: Stroke Prevention and Pitfalls. Open Cardiovasc Med J. 2016;10:94-104doi: 10.2174/1874192401610010094.
Patel, A., Goddeau, R. P., & Henninger, N. (2016). Newer Oral Anticoagulants: Stroke Prevention and Pitfalls. The open cardiovascular medicine journal, 1094-104. https://doi.org/10.2174/1874192401610010094
Patel, Anand, et al. "Newer Oral Anticoagulants: Stroke Prevention and Pitfalls." The open cardiovascular medicine journal vol. 10 (2016): 94-104. doi: https://doi.org/10.2174/1874192401610010094
Patel A, Goddeau RP, Henninger N. Newer Oral Anticoagulants: Stroke Prevention and Pitfalls. Open Cardiovasc Med J. 2016 May 27;10:94-104. doi: 10.2174/1874192401610010094. eCollection 2016. PMID: 27347226; PMCID: PMC4897006.
Copy Download .nbib Format: NLM
Potential for a New Coronary Thrombolytic Plateau.

Journal of thrombosis and thrombolysis

Topol EJ.
PMID: 10602553
J Thromb Thrombolysis. 1996;3(2):127-134. doi: 10.1007/BF00132405.

The GUSTO-I trial provided definitive evidence that early and complete thrombolysis are closely associated with clinical outcome. However, in this trial the best thrombolytic strategy, consisting of accelerated t-PA, aspirin, and heparin, only yielded restoration of brisk flow (TIMI...

Cite
Topol EJ. Potential for a New Coronary Thrombolytic Plateau. J Thromb Thrombolysis. 1996;3(2):127-134doi: 10.1007/BF00132405.
Topol, E. J. (1996). Potential for a New Coronary Thrombolytic Plateau. Journal of thrombosis and thrombolysis, 3(2), 127-134. https://doi.org/10.1007/BF00132405
Topol. "Potential for a New Coronary Thrombolytic Plateau." Journal of thrombosis and thrombolysis vol. 3,2 (1996): 127-134. doi: https://doi.org/10.1007/BF00132405
Topol EJ. Potential for a New Coronary Thrombolytic Plateau. J Thromb Thrombolysis. 1996;3(2):127-134. doi: 10.1007/BF00132405. PMID: 10602553.
Copy Download .nbib Format: NLM
New developments in anticoagulation for atrial fibrillation.

Current treatment options in cardiovascular medicine

Usman MH, Notaro LA, Patel H, Ezekowitz MD.
PMID: 18814828
Curr Treat Options Cardiovasc Med. 2008 Sep;10(5):388-97. doi: 10.1007/s11936-008-0030-0.

The incidence of stroke in patients with atrial fibrillation (AF) is five times greater than that in age-matched controls. Warfarin reduces this incidence by two thirds and is the most effective agent for this indication. However, despite its efficacy,...

Cite
Usman MH, Notaro LA, Patel H, et al. New developments in anticoagulation for atrial fibrillation. Curr Treat Options Cardiovasc Med. 2008;10(5):388-97doi: 10.1007/s11936-008-0030-0.
Usman, M. H., Notaro, L. A., Patel, H., & Ezekowitz, M. D. (2008). New developments in anticoagulation for atrial fibrillation. Current treatment options in cardiovascular medicine, 10(5), 388-97. https://doi.org/10.1007/s11936-008-0030-0
Usman, M Haris U, et al. "New developments in anticoagulation for atrial fibrillation." Current treatment options in cardiovascular medicine vol. 10,5 (2008): 388-97. doi: https://doi.org/10.1007/s11936-008-0030-0
Usman MH, Notaro LA, Patel H, Ezekowitz MD. New developments in anticoagulation for atrial fibrillation. Curr Treat Options Cardiovasc Med. 2008 Sep;10(5):388-97. doi: 10.1007/s11936-008-0030-0. PMID: 18814828.
Copy Download .nbib Format: NLM
Future therapies for the prevention and treatment of venous and arterial thrombosis.

Expert opinion on investigational drugs

McKean ML, Adelman SJ.
PMID: 15991961
Expert Opin Investig Drugs. 1998 May;7(5):687-90. doi: 10.1517/13543784.7.5.687.

The incidence of thrombosis as a complication of invasive surgery, in cancer patients, as a cause or complication of stroke, acute myocardial infarction (AMI), thrombolysis, unstable angina (UA) or angioplasty is substantial. To better serve this patient population in...

Cite
McKean ML, Adelman SJ. Future therapies for the prevention and treatment of venous and arterial thrombosis. Expert Opin Investig Drugs. 1998;7(5):687-90doi: 10.1517/13543784.7.5.687.
McKean, M. L., & Adelman, S. J. (1998). Future therapies for the prevention and treatment of venous and arterial thrombosis. Expert opinion on investigational drugs, 7(5), 687-90. https://doi.org/10.1517/13543784.7.5.687
McKean, M L, and Adelman, S J. "Future therapies for the prevention and treatment of venous and arterial thrombosis." Expert opinion on investigational drugs vol. 7,5 (1998): 687-90. doi: https://doi.org/10.1517/13543784.7.5.687
McKean ML, Adelman SJ. Future therapies for the prevention and treatment of venous and arterial thrombosis. Expert Opin Investig Drugs. 1998 May;7(5):687-90. doi: 10.1517/13543784.7.5.687. PMID: 15991961.
Copy Download .nbib Format: NLM
Thromboprophylaxis in total hip-replacement surgery in Europe: acenocoumarol, fondaparinux, dabigatran and rivaroxban.

Expert review of pharmacoeconomics & outcomes research

Ivanovic N, Beinema M, Brouwers JR, Naunton M, Postma MJ.
PMID: 20528430
Expert Rev Pharmacoecon Outcomes Res. 2007 Feb;7(1):49-58. doi: 10.1586/14737167.7.1.49.

This paper reviews the clinical and pharmacoeconomic studies that have been conducted within Europe for patients undergoing elective hip-replacement surgery. Additionally, we offer a perspective on the possible future clinical use of new agents in orthopedic surgery, such as...

Cite
Ivanovic N, Beinema M, Brouwers JR, et al. Thromboprophylaxis in total hip-replacement surgery in Europe: acenocoumarol, fondaparinux, dabigatran and rivaroxban. Expert Rev Pharmacoecon Outcomes Res. 2007;7(1):49-58doi: 10.1586/14737167.7.1.49.
Ivanovic, N., Beinema, M., Brouwers, J. R., Naunton, M., & Postma, M. J. (2007). Thromboprophylaxis in total hip-replacement surgery in Europe: acenocoumarol, fondaparinux, dabigatran and rivaroxban. Expert review of pharmacoeconomics & outcomes research, 7(1), 49-58. https://doi.org/10.1586/14737167.7.1.49
Ivanovic, Natasa, et al. "Thromboprophylaxis in total hip-replacement surgery in Europe: acenocoumarol, fondaparinux, dabigatran and rivaroxban." Expert review of pharmacoeconomics & outcomes research vol. 7,1 (2007): 49-58. doi: https://doi.org/10.1586/14737167.7.1.49
Ivanovic N, Beinema M, Brouwers JR, Naunton M, Postma MJ. Thromboprophylaxis in total hip-replacement surgery in Europe: acenocoumarol, fondaparinux, dabigatran and rivaroxban. Expert Rev Pharmacoecon Outcomes Res. 2007 Feb;7(1):49-58. doi: 10.1586/14737167.7.1.49. PMID: 20528430.
Copy Download .nbib Format: NLM
Transitions of care in anticoagulated patients.

Journal of multidisciplinary healthcare

Michota F.
PMID: 23818798
J Multidiscip Healthc. 2013 Jun 20;6:215-28. doi: 10.2147/JMDH.S44068. Print 2013.

Anticoagulation is an effective therapeutic means of reducing thrombotic risk in patients with various conditions, including atrial fibrillation, mechanical heart valves, and major surgery. By its nature, anticoagulation increases the risk of bleeding; this risk is particularly high during...

Cite
Michota F. Transitions of care in anticoagulated patients. J Multidiscip Healthc. 2013;6:215-28doi: 10.2147/JMDH.S44068.
Michota, F. (2013). Transitions of care in anticoagulated patients. Journal of multidisciplinary healthcare, 6215-28. https://doi.org/10.2147/JMDH.S44068
Michota, Franklin. "Transitions of care in anticoagulated patients." Journal of multidisciplinary healthcare vol. 6 (2013): 215-28. doi: https://doi.org/10.2147/JMDH.S44068
Michota F. Transitions of care in anticoagulated patients. J Multidiscip Healthc. 2013 Jun 20;6:215-28. doi: 10.2147/JMDH.S44068. Print 2013. PMID: 23818798; PMCID: PMC3693821.
Copy Download .nbib Format: NLM
Cardiac arrest due to left circumflex coronary artery embolism as a complication of subtherapeutic oral anticoagulation in a patient with mitral and aortic mechanical valve prostheses.

Postepy w kardiologii interwencyjnej = Advances in interventional cardiology

Protasiewicz M, Rojek A, Gajek J, Mysiak A.
PMID: 24570697
Postepy Kardiol Interwencyjnej. 2013;9(1):97-100. doi: 10.5114/pwki.2013.34034. Epub 2013 Mar 21.

We report a case of a 65-year-old female patient after replacement of aortic and mitral valve with mechanical prostheses and implantation of a pacemaker hospitalized in our clinic due to acute coronary syndrome complicated with cardiac arrest due to...

Cite
Protasiewicz M, Rojek A, Gajek J, et al. Cardiac arrest due to left circumflex coronary artery embolism as a complication of subtherapeutic oral anticoagulation in a patient with mitral and aortic mechanical valve prostheses. Postepy Kardiol Interwencyjnej. 2013;9(1):97-100doi: 10.5114/pwki.2013.34034.
Protasiewicz, M., Rojek, A., Gajek, J., & Mysiak, A. (2013). Cardiac arrest due to left circumflex coronary artery embolism as a complication of subtherapeutic oral anticoagulation in a patient with mitral and aortic mechanical valve prostheses. Postepy w kardiologii interwencyjnej = Advances in interventional cardiology, 9(1), 97-100. https://doi.org/10.5114/pwki.2013.34034
Protasiewicz, Marcin, et al. "Cardiac arrest due to left circumflex coronary artery embolism as a complication of subtherapeutic oral anticoagulation in a patient with mitral and aortic mechanical valve prostheses." Postepy w kardiologii interwencyjnej = Advances in interventional cardiology vol. 9,1 (2013): 97-100. doi: https://doi.org/10.5114/pwki.2013.34034
Protasiewicz M, Rojek A, Gajek J, Mysiak A. Cardiac arrest due to left circumflex coronary artery embolism as a complication of subtherapeutic oral anticoagulation in a patient with mitral and aortic mechanical valve prostheses. Postepy Kardiol Interwencyjnej. 2013;9(1):97-100. doi: 10.5114/pwki.2013.34034. Epub 2013 Mar 21. PMID: 24570697; PMCID: PMC3915951.
Copy Download .nbib Format: NLM
New prospective for the management of low-risk pulmonary embolism: prognostic assessment, early discharge, and single-drug therapy with new oral anticoagulants.

Scientifica

Squizzato A.
PMID: 24278706
Scientifica (Cairo). 2012;2012:502378. doi: 10.6064/2012/502378. Epub 2012 Dec 17.

Patients with pulmonary embolism (PE) can be stratified into two different prognostic categories, based on the presence or absence of shock or sustained arterial hypotension. Some patients with normotensive PE have a low risk of early mortality, defined as

Cite
Squizzato A. New prospective for the management of low-risk pulmonary embolism: prognostic assessment, early discharge, and single-drug therapy with new oral anticoagulants. Scientifica (Cairo). 2012;2012:502378doi: 10.6064/2012/502378.
Squizzato, A. (2012). New prospective for the management of low-risk pulmonary embolism: prognostic assessment, early discharge, and single-drug therapy with new oral anticoagulants. Scientifica, 2012502378. https://doi.org/10.6064/2012/502378
Squizzato, Alessandro. "New prospective for the management of low-risk pulmonary embolism: prognostic assessment, early discharge, and single-drug therapy with new oral anticoagulants." Scientifica vol. 2012 (2012): 502378. doi: https://doi.org/10.6064/2012/502378
Squizzato A. New prospective for the management of low-risk pulmonary embolism: prognostic assessment, early discharge, and single-drug therapy with new oral anticoagulants. Scientifica (Cairo). 2012;2012:502378. doi: 10.6064/2012/502378. Epub 2012 Dec 17. PMID: 24278706; PMCID: PMC3820448.
Copy Download .nbib Format: NLM
Showing 1 to 12 of 259 entries